Antibody Information

General Information of This Antibody

Antibody ID	ANI0TEFTG
Antibody Name	BCMA-Ab1
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG
Antigen Name	Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

MEDI-2228 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	61.00% (MTD)
Patients Enrolled	Eligible pts were 18 years old with confirmed relapsed/refractory multiple myeloma (R/R MM) as defined by International Myeloma Working Group consensus criteria, had measurable disease, and had an Eastern Cooperative Oncology Group performance status 1. Pts had to have progressed after treatment with three classes of standard-of-care anti-myeloma drugs, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs). Click to Show/Hide
Administration Dosage	Administered in the dose of 0.0125-0.20 mg/kg intravenously every 3 weeks (Q3W); The maximum tolerated dose was 0.14 mg/kg Q3W.
*Related Clinical Trial*
NCT Number	NCT03489525	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of MEDI2228 in subjects with relapsed/refractory multiple myeloma.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82.05% (Day 31)
Method Description	The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
In Vivo Model	NSG mice model
In Vitro Model	Plasma cell myeloma	MM1.S cells	CVCL_8792
Experiment 2 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.46% (Day 31)
Method Description	The inhibitory activity of MEDI-2228+NK against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
In Vivo Model	NSG mice model
In Vitro Model	Plasma cell myeloma	MM1.S cells	CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.94% (Day 31)
Method Description	The inhibitory activity of MEDI-2228+NK+Dara against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
In Vivo Model	NSG mice model
In Vitro Model	Plasma cell myeloma	MM1.S cells	CVCL_8792

Obtained from the Model Organism Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC			[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67.99% (Day 24)
Method Description	The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vivo.The cells were treated with 0.4 mg/kg MEDI-2228.
In Vivo Model	CB17 SCID mice model
Experiment 2 Reporting the Activity Date of This ADC			[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.12% (Day 24)
Method Description	The inhibitory activity combination of M2 and btz for 2 weeks against cancer cell growth was evaluated in various human cancer cell lines in vivo.
In Vivo Model	CB17 SCID mice model

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[3]
Efficacy Data	Half Maximal Effective Dose (EC50)	189.70 ng/mL
Method Description	The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Plasma cell myeloma	RPMI-8226 cells	CVCL_0014

References

Ref 1	Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. Blood (2020) 136 (Supplement 1): 2627.
Ref 2	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin Cancer Res. 2021 Oct 1;27(19):5376-5388.
Ref 3	A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.